In this study we aim to determine the genotype distribution and allele frequencies of common TPMT (*2, *3A, *3B and *3C) polymorphisms in Turkish children with acute leukemia. The study population consisted of 169 patients aged between 1 and 15 years who were admitted to Losante Pediatric Hematology and Children's Hospital with the diagnosis of acute leukemia.
Drug metabolizing enzymes play a role in the neutralizing of xenobiotics and biotransformation of drugs. 1 Polymorphisms in the drug-metabolizing enzyme coding genes change the activity of these enzymes for their substrates. Thiopurine S-methyltransferase (TPMT) is a cytosolic methylating enzyme that preferentially catalyzes the S-methylation (inactivation) of aromatic and heterocyclic sulfhydryl compounds, which include anticancer thiopurine groups such as mercaptopurine, thioguanine, and azathioprine. 2, 3 These medications are currently used to treat many diseases, such as cancers, autoimmune diseases and inflammatory diseases. 4, 5 6-Mercaptopurine (6-MP) and 6-thioguanine (6-TG) have been important components of curative therapy for childhood acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML), respectively. 6, 7 6-MP is a prodrug which is activated by intracellular multistep pathway to cytotoxic thioguanine nucleotides (TGNs) that are incorporated into DNA repair pathway and trigger cell death. 8 TPMT displays genetic polymorphisms in different ethnic groups, including Caucasians, Africans, African-Americans, and Asians. Additionally TPMT has been associated with high levels of 6-MP metabolite levels and toxicity. 9 The TPMT is localized on chromosome 6p22.3 and consists of 10 exons. 10 To date more than 20 SNPs for TPMT have been reported. [11] [12] [13] Four alleles (TPMT*2, *3A, *3B, and *3C) describe for ∼95% of inherited TPMT deficiency and have been biochemically characterized. [14] [15] [16] TPMT *3A allele results in an about 400-fold decrease; TPMT*3B allele results in a fourfold decrease; TPMT*2 allele results 100-fold decrease; TPMT*3C allele results in a 1.4-fold in protein levels. 17, 18 The wild-type allele, TPMT*1, encodes the fully active enzyme. 19 The frequencies of TPMT*2 (238G>C), TPMT*3A (719A>G-460G>A) TPMT *3B (460G>A) and TPMT *3C (719A>G) alleles have been reported in different populations as shown in Table I . The molecular defect in TPMT*2 contains G>C transversion at position 238 that leads to an amino acid substitution at codon 80 Ala>Pro. 20 The TPMT*3A contains two nucleotide transitions G>A and A>G at positions 460 and 719 that lead to the amino acid substitution at codon 154 Ala>Thr and at codon 240 Tyr>Cys. 21 The TPMT*3B contains single nucleotide transition G>A at position 460 that lead to the amino acid substitution at codon 154 Ala>Thr. 22 The TPMT*3C contains A>G transversion at position 719 that leads to the amino acid substitution at codon 240 Tyr>Cys. 23 These alleles are accounted for more than 80% of TPMT in Caucasians [24] . The frequencies of four variant TPMT alleles (TPMT *2, TPMT *3B, TPMT *3C, TPMT *3A) accounting for more than 80% of all low activity cases were determined in children with ALL in Turkish population. 25 The aim of this study is to determine the genotype distribution and allele frequencies o f c o m m o n TPMT*2,*3A, 3B, a n d *3C polymorphisms by melting curve detection analysis with Light Cycler 480 II System in Turkish children with acute leukemia.
Material and Methods

Patients and sample collections
Study population consisted of 169 patients (99 males and 70 females) aged between 1 and 15 years who were admitted to Lösante Pediatric Hematology and Children's Hospital and diagnosed with childhood acute leukemia. Patient characteristics were shown in Table I .
An informed written consent was obtained from all the patients' parents. The study was carried out in accordance with the code of Ethics of 
TPMT genotyping
TPMT polymorphisms analyses were performed by real-time PCR (RT-PCR). Genotyping of TPMT mutations were screened with real time PCR using fluorescence melting curve detection analysis by means of the Light Cycler 480 II System (Roche Diagnostics, Manheim, Germany). For G238C (*2), primers are used which flank the region around the potential mutation place and produce an amplicon of 197 bp. For G460A (*3A, *3B) and A719G (*3A, *3C), two primer pairs are used generating amplicons of 159 bp and respectively 177 bp. The melting-point curve analysis allows a clear identification of wildtype, heterozygous or homozygous genotypes.
Statistical analysis
The chi-square test was used to compare categorical variables. P value of <0.05 was considered statistically significant. Allelic frequencies were calculated by gene-counting method and the genotype distribution with Hardy-Weinberg expectations were determined by c 2 and Fisher's exact tests.
Results
In this study, we performed Real Time PCR method to detect three types of polymorphisms of the human TPMT. Three TPMT polymorphisms; G238C substitution located in exon 5 region, G460A substitution located in exon 7 region, and A719G substitution located in exon 10 region. TPMT genotypes of the most prevalent mutant allele's (TPMT *2, *3A, *3B and *3C) variant genotypes were determined in 169 Turkish children with leukemia who were diagnosed with ALL and AML.
As presented in Table II T h e g e n o t y p e f r e q u e n c i e s o f T P M T polymorphisms in healthy individuals from different countries were given in Table III .
Discussion
T P M T c a t a l y z e s t h e m e t h y l a t i o n o f thiopurine drugs such as azathioprine and 6-mercaptopurine. 26 TPMT enzyme activity is influenced by polymorphisms in the TPMT gene. [27] [28] [29] 
